In HCC, about 50% of cases had aberrantly activated PI3K/AKT/mTOR pathway [22, 23], and about 50% of cases harbored PTEN loss or reduced PTEN levels [24]. The gene discussed is MTOR; the disease is hepatocellular carcinoma.